Scholarlink

<p>The rise of antibiotic resistance among pathogenic bacteria necessitates innovative therapeutic strategies, such as collateral sensitivity where resistance to one antibiotic increases susceptibility to another. We explored the clinical relevance of collateral sensitivity through genetic engineering and experimental evolution in the six critical bacterial pathogens <i>Escherichia coli</i>, <i>Salmonella Typhimurium</i>, <i>Klebsiella pneumoniae</i>, <i>Acinetobacter baumannii</i>, <i>Pseudomonas aeruginosa</i>, and <i>Staphylococcus aureus</i>. Our analysis of <i>E. coli</i> showed that clinically relevant resistance mutations did not confer collateral sensitivity, but we were able to identify at least three novel classes of ciprofloxacin-resistance mutations that cause collateral sensitivity to multiple antibiotics. Further analysis showed that the development of collateral effects differed between the tested species. Collateral sensitivity to gentamicin developed during ciprofloxacin-resistance evolution in almost all tested species, but <i>A. baumannii</i> developed collateral resistance instead. <i>P. aeruginosa</i> consistently developed collateral sensitivity, suggesting its potential for targeted treatment strategies. These findings highlight the complexity of collateral effects and support its therapeutic potential in designing more effective antibiotic regimens.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Evolutionary trajectories determine feasibility of collateral sensitivity-based antibiotic treatment strategies in critical bacterial pathogens

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月6日

查看全文
  • Vatsala Chauhan,
  • Lisa Enkvist,
  • Yuliia Chukhareva,
  • Carl Damell,
  • Eric Cruz Davila,
  • Tasnim M. Islam,
  • Greta Melander,
  • Ellen Paulsson,
  • Adam Sundell,
  • Emily Zweifel,
  • Anna af Klercker,
  • Anna Knöppel,
  • Gerrit Brandis

摘要

The rise of antibiotic resistance among pathogenic bacteria necessitates innovative therapeutic strategies, such as collateral sensitivity where resistance to one antibiotic increases susceptibility to another. We explored the clinical relevance of collateral sensitivity through genetic engineering and experimental evolution in the six critical bacterial pathogens Escherichia coli, Salmonella Typhimurium, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Staphylococcus aureus. Our analysis of E. coli showed that clinically relevant resistance mutations did not confer collateral sensitivity, but we were able to identify at least three novel classes of ciprofloxacin-resistance mutations that cause collateral sensitivity to multiple antibiotics. Further analysis showed that the development of collateral effects differed between the tested species. Collateral sensitivity to gentamicin developed during ciprofloxacin-resistance evolution in almost all tested species, but A. baumannii developed collateral resistance instead. P. aeruginosa consistently developed collateral sensitivity, suggesting its potential for targeted treatment strategies. These findings highlight the complexity of collateral effects and support its therapeutic potential in designing more effective antibiotic regimens.